Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of CREXONT, an extended-release capsule containing Carbidopa and Levodopa, in people with Parkinson disease PD under real-world conditions. This Phase 4 study aims to understand how well CREXONT works in reducing motor symptom fluctuations in participants who are already treated with stable oral Carbidopa-Levodopa regimens. Participants will receive CREXONT extended-release capsules orally, with doses guided by FDA-approved prescribing information. The capsules come in several strengths, and dosing will be adjusted individually to find the best balance between effectiveness and tolerability. The study includes an initial dosing based on prior oral medication and allows optimization throughout the study to meet each participants needs. During the study, participants will complete Parkinsons Disease diaries to track On and Off motor states, and researchers will measure changes in Good On time and Off time by Day 42 compared to baseline. Participants will attend study visits and may receive questionnaires and assessments to monitor their condition and treatment response. The study is open-label, meaning all participants receive CREXONT, and the total participation duration includes baseline and follow-up assessments through Day 42.
Actively Recruiting
Researchers are evaluating BHV-8000 in adults aged 40 to 80 diagnosed with early Parkinsons disease. The study aims to determine if BHV-8000 is effective, safe, and tolerable as a treatment. This Phase 23 trial is led by Biohaven Therapeutics Ltd. and includes a double-blind phase followed by an open-label phase to assess the treatments impact over time. Participants will be randomly assigned to receive either BHV-8000 at doses of 10 mg or 20 mg taken orally, or a matching placebo during the 48-week double-blind phase. After this, all participants enter a 48-week open-label phase where they receive BHV-8000. This design allows comparison between the study drug and placebo, followed by extended access to the active treatment. During the study, participants will be regularly assessed for Parkinsons disease progression using the Movement Disorder Society-Unified Parkinsons Disease Rating Scale MDS-UPDRS and other clinical measures. Safety will be monitored through recording adverse events and laboratory tests up to 96 weeks. The primary outcome is the time to first worsening event on the MDS-UPDRS Part II within 48 weeks. Participants are expected to remain in the study for up to 96 weeks of observation and treatment.
Actively Recruiting
Researchers are conducting a randomized controlled trial to compare survival outcomes between robotic-assisted laparoscopy and open hysterectomy with lymph node assessment for early-stage cervical cancer. The study aims to determine if robotic hysterectomy with tumor containment before colpotomy is not worse than abdominal hysterectomy in terms of disease-free survival. It includes patients with specific cervical cancer stages and tumor sizes suitable for surgery. Participants will undergo either a radical or simple hysterectomy using either traditional open surgery or a robotic-assisted technique. In the robotic group, the vagina is closed before colpotomy, and certain vaginal manipulators are not allowed. Both groups may have salpingectomy and oophorectomy with or without ovarian transposition. Surgeons will document operative details, including any complications, blood loss, and reasons for conversion to open surgery. During the trial, participants will be closely monitored with preoperative assessments like labs, EKG, and MRI to confirm eligibility. Surgical findings and complications will be recorded. The primary outcome measured is survival at 36 months. Participants must provide informed consent and undergo follow-up to assess disease status and survival over the study period, which extends until 2030.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a community participatory hydration intervention to improve hydration practices in schools over a three-year period. The study focuses on districts that have recently installed hydration stations and are following policies aimed at promoting healthy hydration and equal access to drinking water. The trial examines its potential effects on dental health and obesity prevention among school children. The intervention lasts four months and includes providing refillable water bottles to students in schools equipped with hydration stations. Additional components involve social marketing, behavioral reinforcement, and educational outreach. Schools are randomly assigned in a stepped-wedge design, where clusters progressively receive the intervention. The study compares an assessment-only control group with an experimental group receiving the hydration intervention. Participants include students from kindergarten through fifth grade who eat lunch in the cafeteria, with specific assessments for those enrolled in third grade and followed through fifth grade. The study collects data on hydration station usage, BMI z-scores, dental caries, beverage consumption, academic outcomes, and school staff knowledge. Evaluations occur over the full three years, with surveys administered to students and staff. The trial also monitors water bottle use, beverage sales, and participation in the National School Lunch Program.
Actively Recruiting
Healthy Volunteer
Researchers are conducting Enroll-HD, a large, ongoing observational study that combines and expands previous Huntingtons disease HD registries across multiple continents, including Europe, North America, Australasia, and Latin America. This study collects longitudinal clinical data and biological samples from individuals with manifest HD, those carrying or at risk of carrying the HD gene mutation, and control participants without the mutation. The goal is to build a rich database to support research into disease progression, prognosis, and developing clinical trial endpoints. Participants include those with diagnosed HD, pre-manifest carriers, relatives with unknown or negative genotype status, family controls, and community controls. The study involves annual assessments with no planned end date, allowing for long-term data collection. Researchers collect demographic, clinical, family history, genetic, and blood sample information systematically from over 150 sites worldwide. During the study, participants undergo motor, functional, behavioral, and cognitive assessments using standardized tools such as the Unified Huntingtons Disease Rating Scale and Problem Behaviors Assessment-Short. Data are updated at each visit, including clinical signs and genotyping results. The study database is periodically made available to researchers globally, and participants may contribute for many years, helping to advance understanding and support future interventional studies in HD.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the Carillon Mitral Contour System CMCS in treating patients with heart failure who also have functional mitral regurgitation FMR. This prospective, randomized, double-blinded, sham-controlled trial aims to better understand how this device may impact heart function and symptoms in people with this condition. Participants will be randomly assigned to one of two groups one group will receive the Carillon implant along with guideline-directed heart failure medications, while the other group will receive only the heart failure medications and a sham procedure to preserve blinding. Before randomization, patients will undergo specific heart imaging tests and evaluations to determine eligibility and suitability for the device placement. After the procedure, participants will have follow-up visits at 1, 6, 12, 18, and 24 months to monitor safety and heart function. After 24 months, all participants will be informed of their group assignment and followed annually for an additional three years. During the study, researchers will assess various health outcomes including freedom from major adverse events at 12 months and clinical improvement at 24 months. Additional measures will include changes in heart valve function, heart size, walking ability, heart failure symptoms, hospitalizations, and quality of life. Participants will have regular heart imaging, clinical evaluations, and questionnaires to track these outcomes. The total participation time may extend up to five years with long-term monitoring to better understand the devices impact over time.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a new intensive health behavior and lifestyle program called Virtual Housecalls VHC to treat class I adolescent obesity in pediatric primary care. This pragmatic randomized clinical trial includes 250 adolescents aged 12 to 15 years with non-severe obesity and their participating parent or caregiver. The study aims to find scalable ways to provide the recommended treatment dose and effectively address obesity in this setting. Participants in the VHC group receive 26 hours of treatment combining in-person pediatric primary care provider PPCP visits every three months with six months of virtual sessions by a behavior coach. These virtual visits occur weekly for three months and then every two weeks for the next three months, along with weekly exercise videos. The control group receives enhanced treatment as usual, which includes standard care from their PPCP augmented with educational materials delivered on the same schedule as the VHC group. All PPCPs are trained on obesity treatment guidelines and receive progress reports about participants at 3, 6, and 12 months. Throughout the study, participants complete assessments at 0, 3, 6, and 12 months measuring body mass index BMI, diet, physical activity, parenting, and home environment. The primary outcome is BMI change at 6 months, with additional measurements including BMI maintenance, energy intake, diet quality, physical activity, and treatment dose up to 12 months. This study lasts 12 months and involves regular monitoring to evaluate the interventions effects and adherence.